StreetAlpha.app
Home › Stocks › ADPT

Adaptive Biotechnologies Corp (ADPT)

Healthcare
$28.49
▲ +2.22%
LAST CLOSE · NOV 17

Adaptive Biotechnologies makes immune system based cancer tests and sells immune data to clinicians and drug developers. It last closed at $28.49 on Nov 17, up 2.22% on the day. ADPT reports earnings on Thu, Feb 4, 2027. The average 12-month price target from 5 analysts is $32.40 (+13.7% from the last close), with a high of $35.00 and a low of $27.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell).

AI Auto Pilots
Is ADPT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$298.0M
+17.9% vs a year ago
Net income
−$70.5M
−23.7% margin
EPS (diluted)
−$0.45
Free cash flow
−$8.8M
−3.0% margin
Valuation
Market cap
$4.6B
161.9M shares
P/E
–
No P/E while losing money
Price to sales
15.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$75.6M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
$176.2M
Shares outstanding
161.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $154.3M$154.3MFY2021FY2022: $185.3M$185.3MFY2022FY2023: $170.3M$170.3MFY2023FY2024: $179.0M$179.0MFY2024FY2025: $277.0M$277.0MFY2025

From ADPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 4
2027 · Time not announced
Consensus EPS forecast
-$0.04
$80.6M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
4 Buy1 Hold0 Sell
Each firm's latest rating on ADPT in the past 90 days
Average 12-month target
$32.40
▲ 13.7% upside

Based on 5 analysts who set a price target on ADPT in the past 90 days. The average target is $32.40, with a high of $35.00 and a low of $27.00, compared with the last close of $28.49.

Low $27.00Avg $32.40High $35.00
Blue marker: last close $28.49
Highest target$35.00
Average target$32.40
Lowest target$27.00
Latest rating changes
GuggenheimTarget raised
Nov 10Buy$32 → $34
TD CowenTarget raised
Oct 13Buy$28 → $32
Morgan StanleyTarget raised
Oct 13Hold$22 → $27
GuggenheimTarget raised
Oct 1Buy$25 → $32
Goldman SachsInitiated
Sep 29Buy$35
DateFirmActionRatingPrice target
Nov 10GuggenheimTarget raisedBuy$32 → $34
Oct 13TD CowenTarget raisedBuy$28 → $32
Oct 13Morgan StanleyTarget raisedHold$22 → $27
Oct 1GuggenheimTarget raisedBuy$25 → $32
Sep 29Goldman SachsInitiatedBuy$35
Loading…

Technical Analysis

ADPT · as of the Nov 17 close · updated after every close
Uptrend

The stock is 4% above its 20 day and 5% above its 50 day average. It is 29% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 54). The nearest support is the Pivot at $28.43, and the nearest resistance the swing high (Oct 28) at $29.05.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 6.0%/day
Key levels
$32.1352 week high+12.8%
$29.24Pivot R1+2.6%
$29.05Swing high (Oct 28)+2.0%
$28.49Last close
$28.43Pivot−0.2%
$27.68Pivot S1−2.8%
$27.4620 day average−3.6%
$27.0650 day average−5.0%
$26.73Swing low (Sep 22)−6.2%
$25.30100 day average−11.2%
$20.19200 day average−29.1%
$12.0052 week low−57.9%
Indicators
RSI (14)54.43Middle of its rangeNeutral
MACD0.70Above its signal lineBullish
Stochastic50.0Middle of its rangeNeutral
ADX (14)17.7No clear trend
Williams %R-49.7Oversold below −80, overbought above −20Neutral
CCI (20)46.0Oversold below −100, overbought above 100Neutral
Rate of change+10.4%Change over 10 sessionsBullish
ATR (14)$1.72Typical daily range, 6.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ADPT

What happened before

See how ADPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ADPT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ADPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ADPT in the last 90 days.

Loading…

See today’s whale options flow across the market →

ADPT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲185 buying vs 139 selling
  • ▲Held by funds +6.9 pts
  • ▲Funds holding +30
  • ▲Superinvestors: 5 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding335305+9.8%
In funds' top 1052+150.0%
Held by funds103.2%96.3%+6.9 pts
New / increased64 / 12146 / 109+19.4%
Reduced / sold out107 / 3288 / 42+6.9%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ADPT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADPT is in one of them and how their past ADPT trades turned out.

ADPT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ADPT in an article yet. Here's the latest on the wider market.

ADPT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Mar 8
Who traded ADPT · since 2022
Latest 1 filing
$1K – $15KTraded Feb 14, 2022Filed Mar 8, 2022
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$1K – $15KFeb 14, 2022Mar 8, 202222 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a life sciences company based in Seattle, Washington. It uses sequencing and data analysis of the immune system to develop medical tests and products. Its main product, clonoSEQ, measures residual disease in patients with blood cancers and is sold to clinicians. It also runs testing for biopharmaceutical companies developing new drugs and licenses its immune system data to drug developers.

Headquarters
Seattle, WA
Founded
2009